fasudil has been researched along with Cancer of the Urinary Tract in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, H | 1 |
| Kamai, T | 1 |
| Hayashi, K | 1 |
| Anzai, N | 1 |
| Shirataki, H | 1 |
| Mizuno, T | 1 |
| Yamaguchi, Y | 1 |
| Masuda, A | 1 |
| Yuki, H | 1 |
| Betsunoh, H | 1 |
| Yashi, M | 1 |
| Fukabori, Y | 1 |
| Yoshida, K | 1 |
1 other study available for fasudil and Cancer of the Urinary Tract
| Article | Year |
|---|---|
The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Prol | 2014 |